Drugs / ARO-MAPT-SC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07221344 | Nov 2025 → Jun 2027 expected | Alzheimer disease | Arrowhead Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-MAPT-SC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07221344 ↗ |
| Route | Subcutaneous | “by subcutaneous (SC) injection” NCT07221344 ↗ |